This comparison sets ARA-290 and FOX-04-DRI side by side on structural class, synthesis route, and the documentation a laboratory needs to build into a specification for 2026 procurement. Both are supplied for research use only, and the acceptance criteria written for one rarely transfer to the other.
- ARA-290 is an 11-residue linear peptide; FOX-04-DRI is a longer D-retro-inverso fusion peptide of roughly 30 residues.
- ARA-290 fits standard SPPS specification and faster analytical turnaround for 2026 research procurement.
- FOX-04-DRI requires extended synthesis and added stereochemistry verification before lot release.
- Comparing ara-290 and fox-04-dri peptides side by side means matching acceptance criteria to structural class, not common name.
Why this matters
A specification that names a peptide by common name alone gives a lab nothing to test against. ARA-290 and FOX-04-DRI differ enough in structural class and synthesis route that acceptance criteria written for one rarely apply to the other without rework. Procurement teams comparing the two in 2026 need to know which analytical methods apply, what chain length means for synthesis lead time, and how lot documentation should be scoped before a purchase order goes out.
Purity confirmation is the first checkpoint in either case. Labs that require third-party purity testing as a standing requirement should confirm that a supplier's certificate of analysis references the exact synthesis route used for the lot, not a generic peptide-class average.
What defines the comparison
- Structural class — linear single-domain peptide versus fusion peptide with a cell-penetrating domain
- Chain length — residue count drives synthesis time and analytical scope
- Synthesis route — standard L-amino acid SPPS versus D-retro-inverso backbone construction
- Analytical scope — standard reverse-phase HPLC and mass spec versus added stereochemistry confirmation
- Documentation requirement — sequence identity confirmation versus fusion-domain and backbone verification
- Lead time implication — shorter single-stage synthesis versus extended multi-stage production
ARA-290 and FOX-04-DRI at a glance
| Peptide | Structural class | Approximate chain length | Synthesis complexity | Primary documentation focus |
|---|---|---|---|---|
| ARA-290 | Linear, single-domain (EPO-derived helix sequence) | 11 residues | Standard SPPS, single-chain synthesis | Sequence identity plus HPLC purity confirmation |
| FOX-04-DRI | D-retro-inverso fusion peptide with cell-penetrating domain | Approximately 30 residues | Extended SPPS with D-amino acid backbone and fusion sequence | Fusion-domain confirmation plus retro-inverso stereochemistry verification |
1. ARA-290: best for standard single-chain peptide specification review
ARA-290 is an 11-residue linear peptide derived from a helical region of erythropoietin, referenced in preclinical research literature under this designation. Its short chain length and single-domain structure make it a straightforward case for labs writing standard synthesis and analytical acceptance criteria. ARA-290 is the simpler of the two compounds to specify, verify, and document at the lot level.
ARA-290 pros:
- Standard SPPS methods apply without added stereochemistry steps
- Shorter chain reduces batch-to-batch sequence variability during synthesis
- Faster MS and HPLC confirmation given lower structural complexity
- Acceptance criteria align closely with conventional peptide QC templates
ARA-290 cons:
- Single-domain structure has no scope for protocols studying fusion-peptide behavior
- Narrower structural profile limits use in cell-penetrating peptide comparisons
Best for: labs specifying short-chain, single-domain peptides with conventional synthesis and analytical review timelines.
Verdict: Specify. ARA-290 fits standard research peptide documentation workflows without added analytical scope.
2. FOX-04-DRI: best for fusion-peptide and D-retro-inverso synthesis review
FOX-04-DRI is a longer, D-retro-inverso peptide construct built around a fusion of a cell-penetrating sequence and an interfering domain, referenced in preclinical senescence-related literature. At roughly 30 residues, it is several times longer than ARA-290, and its D-amino acid backbone requires synthesis and analytical steps that standard L-peptide protocols do not call for.
FOX-04-DRI pros:
- Fusion-domain design supports protocols requiring cell-penetrating peptide behavior in the specification
- D-retro-inverso backbone gives labs a structurally distinct case for building protease-resistance criteria into acceptance testing
- Longer sequence produces more data points for full-length MS confirmation
FOX-04-DRI cons:
- Extended synthesis with D-amino acids and a fused sequence increases production complexity and lengthens verification
- Retro-inverso stereochemistry confirmation requires analytical method scope beyond standard reverse-phase HPLC
- Multi-domain peptide lots typically carry longer production lead times than single-domain peptides
Best for: labs requiring extended fusion-peptide synthesis with D-retro-inverso stereochemistry documented at the lot level.
Verdict: Specify with expanded analytical scope. FOX-04-DRI belongs in protocols that already account for longer synthesis and verification cycles.
“A specification without an analytical method attached is not a specification, it is a description.”
How this comparison was structured
The comparison follows the same five stages used to scope any custom or catalog peptide order:
- Define — structural class, chain length, and intended analytical method are set before synthesis begins
- Plan — synthesis route (standard SPPS or D-retro-inverso) is matched to the sequence
- Produce — the peptide is synthesized to the defined sequence and backbone chemistry
- Verify — HPLC purity and MS identity confirmation are run against the written acceptance criteria; FOX-04-DRI adds stereochemistry confirmation at this stage
- Document — lot records, including analytical testing services for peptide purity results, are issued with the certificate of analysis
Storage and stability documentation matter after synthesis too. Labs holding lyophilized stock of either peptide should check for the visible and analytical signs covered in how to tell if a lyophilized peptide has degraded before pulling a vial for a new protocol in 2026.
Which peptide fits your protocol
For protocols built around a short, single-domain sequence with conventional synthesis and analytical timelines, ARA-290 is the specification to write. For protocols requiring a cell-penetrating fusion peptide with D-retro-inverso backbone documentation, FOX-04-DRI is the compound to specify, with the understanding that synthesis and verification will run longer. Neither substitutes for the other; the choice is set by the structural requirement in the research brief, not by convenience.
Request a custom synthesis quote
Submit a scientific brief for ARA-290, FOX-04-DRI, or a related sequence.
FAQ
What is the structural difference between ARA-290 and FOX-04-DRI?
ARA-290 is an 11-residue linear peptide derived from an erythropoietin helix sequence, while FOX-04-DRI is a longer D-retro-inverso fusion peptide of roughly 30 residues built from a cell-penetrating domain fused to an interfering sequence. The chain length and backbone chemistry differ enough that separate acceptance criteria apply to each.
Is ARA-290 easier to synthesize than FOX-04-DRI?
Yes. ARA-290’s short, single-domain sequence uses standard SPPS methods, while FOX-04-DRI’s D-retro-inverso backbone and fusion sequence require extended synthesis and added verification steps. This makes ARA-290 the faster specification to produce and document.
What purity specification should a lab request for ARA-290 or FOX-04-DRI?
Both should carry a written HPLC purity acceptance criterion tied to the specific synthesis lot, confirmed by mass spectrometry for sequence identity. FOX-04-DRI additionally needs a documented method for confirming D-retro-inverso stereochemistry, which standard reverse-phase HPLC alone does not verify.
How should ARA-290 and FOX-04-DRI be stored before reconstitution?
Both are supplied lyophilized and should be stored per the certificate of analysis storage conditions until reconstitution. Checking for visible or analytical signs of degradation before use is standard practice for any lyophilized peptide lot held past its initial testing date.
Does FOX-04-DRI require different analytical methods than standard peptides?
Yes. Beyond standard reverse-phase HPLC and MS identity confirmation, FOX-04-DRI’s D-retro-inverso backbone requires an analytical method scoped to confirm stereochemistry, which is not part of a typical L-peptide acceptance protocol.
Can custom lots of ARA-290 or FOX-04-DRI be produced to a written specification?
Custom synthesis of both sequence types can be scoped through a defined specification and feasibility review, with synthesis, purification, and analytical characterization run against project-specific acceptance criteria.
How often should stored peptide lots be retested for purity?
Retest cadence should be set by the lot’s original certificate of analysis and storage conditions rather than a fixed calendar interval, with retesting scheduled sooner for peptides held near the edge of their documented stability window.
What documentation should accompany an ARA-290 or FOX-04-DRI research order?
A complete order should include a certificate of analysis referencing the specific lot, HPLC purity data, MS identity confirmation, and, for FOX-04-DRI, stereochemistry verification tied to the D-retro-inverso synthesis route.
One last thing
The residue-count gap between these two peptides, 11 versus roughly 30, is the single fact that should drive every downstream decision in 2026: synthesis timeline, analytical method scope, and lot documentation depth all scale with chain length and backbone chemistry, not with which compound sounds more advanced on a research brief.
Related guides